Tracers / [177Lu]Lu-DOTA-MI-exendin-4
[177Lu]Lu-DOTA-MI-exendin-4
Also written as [Lu-177]Lu-DOTA-MI-exendin-4
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated exendin-4 peptide analogue (GLP-1 receptor-targeting peptide) with Met-Ile cleavable linker
- Target / mechanism
- Targets the glucagon-like peptide-1 receptor (GLP-1R) PMID 37265006
- Clinical application
- Radionuclide therapy for GLP-1R-expressing tumours (e.g., insulinoma), aiming to reduce renal retention compared to standard DOTA-exendin-4 PMID 37265006
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | — | >90% | DOTA-MI-exendin-4 piCHEM, Raaba-Grambach, Austria | 37265006 2023 Mol Pharm DOTA-exendin-4 and DOTA-MI-exendin-4 were labeled with 177Lu by incubating |
Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-MI-exendin-4, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 37265006. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 37265006: 'Lys40[Mep((S-)DOTA-Met-Ile-Mal-)]exendin-4 (referred to as DOTA-MI-exendin-4)'.